Patents by Inventor Paul L. Hallenbeck

Paul L. Hallenbeck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140348798
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Application
    Filed: March 7, 2014
    Publication date: November 27, 2014
    Applicant: NOVARTIS AG
    Inventors: Paul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG
  • Publication number: 20120034676
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Application
    Filed: August 12, 2011
    Publication date: February 9, 2012
    Inventors: Paul L. HALLENBECK, Seshidar Reddy Police, Laura M. Hales, Carl M. Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
  • Publication number: 20100129325
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Application
    Filed: October 9, 2009
    Publication date: May 27, 2010
    Applicant: NOVARTIS AG
    Inventors: Paul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG
  • Patent number: 7638318
    Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: December 29, 2009
    Assignee: Norvartis AG
    Inventors: Paul L. Hallenbeck, Seshidar Reddy Police, Laura M. Hales, Carl M. Hay, Shanthi Ganesh, Ling Xu, Jingping Yang, Cheng Cheng
  • Publication number: 20080213884
    Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated.
    Type: Application
    Filed: October 25, 2007
    Publication date: September 4, 2008
    Applicant: Cell Genesys, Inc.
    Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
  • Patent number: 7109029
    Abstract: The present invention provides novel viral vectors and methods useful for the minimization of leaky gene expression, and, in particular, of nonspecific transcriptional read-through of genes. Such constructs may be obtained by the insertion of an insulating sequence into a vector construct, such as for example a termination signal sequence upstream of the transcription initiation site of the respective transcription unit.
    Type: Grant
    Filed: February 22, 2002
    Date of Patent: September 19, 2006
    Assignee: Cell Genesys, Inc.
    Inventors: Lori Clarke, Mario Gorziglia, Paul L. Hallenbeck, John Leonard Jakubczak, Michael Kaleko, Sandrina Phipps
  • Publication number: 20040009588
    Abstract: The invention generally relates to cell-specific expression vectors. It particularly relates to targeted gene therapy using recombinant expression vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional expression vectors and methods for using them. Such vectors are able to selectively replicate in a target cell or tissue to provide a therapeutic benefit in a tissue from the presence of the vector per se or from one or more heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.
    Type: Application
    Filed: June 24, 2003
    Publication date: January 15, 2004
    Applicant: Genetic Therapy, Inc.
    Inventors: Yung-Nien Chang, Paul L. Hallenbeck, Carl M. Hay, David A. Stewart
  • Patent number: 6638762
    Abstract: The invention generally relates to cell-specific expression vectors. It particularly relates to targeted gene therapy using recombinant expression vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional expression vectors and methods for using them. Such vectors are able to selectively replicate in a target cell or tissue to provide a therapeutic benefit in a tissue from the presence of the vector per se or from one or more heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.
    Type: Grant
    Filed: November 19, 1997
    Date of Patent: October 28, 2003
    Assignee: Genetic Therapy, Inc.
    Inventors: Yung-Nien Chang, Paul L. Hallenbeck, Carl M. Hay, David A. Stewart
  • Publication number: 20030129175
    Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.
    Type: Application
    Filed: December 19, 2002
    Publication date: July 10, 2003
    Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
  • Publication number: 20030118570
    Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.
    Type: Application
    Filed: December 19, 2002
    Publication date: June 26, 2003
    Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
  • Publication number: 20030113296
    Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.
    Type: Application
    Filed: December 19, 2002
    Publication date: June 19, 2003
    Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
  • Publication number: 20030104625
    Abstract: The present invention relates to oncolytic adenoviral vectors and their use in methods of gene therapy. Provided is a recombinant viral vector comprising an adenoviral nucleic acid backbone, wherein said nucleic acid backbone comprises in sequential order: A left ITR, a termination signal sequence, an E2F responsive promoter which is operably linked to a gene essential for replication of the recombinant viral vector, an adenoviral packaging signal, and a right ITR.
    Type: Application
    Filed: February 22, 2002
    Publication date: June 5, 2003
    Inventors: Cheng Cheng, Lori Clarke, Sheila Connelly, David Leonard Ennist, Suzanne Forry-Schaudies, Mario Gorziglia, Paul L. Hallenbeck, Carl M. Hay, John Leonard Jakubczak, Michael Kaleko, Sandrina Phipps, Seshidhar Reddy Police, Patricia Clare Ryan, David A. Stewart, Yuefeng Xie
  • Publication number: 20030104624
    Abstract: The present invention provides novel viral vectors and methods useful for the minimization of leaky gene expression, and, in particular, of nonspecific transcriptional read-through of genes. Such constructs may be obtained by the insertion of an insulating sequence into a vector construct, such as for example a termination signal sequence upstream of the transcription initiation site of the respective transcription unit.
    Type: Application
    Filed: February 22, 2002
    Publication date: June 5, 2003
    Inventors: Lori Clarke, Mario Gorziglia, Paul L. Hallenbeck, John Leonard Jakubczak, Michael Kaleko, Sandrina Phipps
  • Patent number: 6551587
    Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: April 22, 2003
    Assignee: Genetic Therapy, Inc.
    Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
  • Publication number: 20030012767
    Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that ihibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.
    Type: Application
    Filed: December 15, 1998
    Publication date: January 16, 2003
    Inventors: PAUL L. HALLENBECK, YUNG-NIEN CHANG, YAWEN L. CHIANG
  • Publication number: 20020137213
    Abstract: This invention relates to mutated adenoviral fiber proteins and adenovirus particles containing such proteins. It further relates to polynucleotides encoding the proteins and vectors containing polynucleotides. It also relates to methods for making and using the adenoviral particles. With the mutated fiber proteins, the adenovirus particles no longer bind to their natural cellular receptor. They can then be “retargeted” to a specific cell type through the addition of a ligand to the virus capsid, which causes the virus to bind to and infect such cell. Specific fiber mutations are listed, which ablate binding to the natural receptor. Adenovirus particles with certain fiber mutations were found to enhance gene transfer to and expression in liver as compared to viral particles with wild-type fiber.
    Type: Application
    Filed: May 30, 2001
    Publication date: September 26, 2002
    Inventors: Paul L. Hallenbeck, Neeraja Idamakanti, John Leonard Jakubczak, Michael Kaleko, Michele Lynette Rollence, Theodore Smith, Susan C. Stevenson, David A. Stewart
  • Patent number: 5998205
    Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that ihibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: December 7, 1999
    Assignee: Genetic Therapy, Inc.
    Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang